CSIMarket Company Name, Ticker, Industry, else..
 
Monte Rosa Therapeutics Inc   (NASDAQ: GLUE)
 
Price: $13.8400 $-0.54 -3.755%
Day's High: $14.3100004196167 Week Perf: -0.72 %
Day's Low: $ 13.79 30 Day Perf: -11.9 %
Volume (M): 804,576 52 Wk High: $ 25.77
Volume (M$): $ 0 52 Wk Avg: $16.68
Open: $14.12 52 Wk Low: $4.79



 Market Capitalization (Millions $) 1,382
 Shares Outstanding (Millions) 100
 Employees 150
 Revenues (TTM) (Millions $) 43
 Net Income (TTM) (Millions $) -130
 Cash Flow (TTM) (Millions $) 81
 Capital Exp. (TTM) (Millions $) 5

Business Description


Monte Rosa Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutics targeting protein degradation pathways. The company aims to harness the body's natural protein degradation system to selectively eliminate disease-causing proteins, potentially leading to the development of novel treatments for various diseases including cancer and genetic disorders. Monte Rosa Therapeutics utilizes its proprietary platform technology to discover and optimize small molecules that can degrade specific proteins, offering a unique approach to drug development.


   Company Address: 321 Harrison Avenue Boston 2118 MA
   Company Phone Number: 949-2643   Stock Exchange / Ticker: NASDAQ GLUE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        1.11% 
CCCC   -2.34%    
CRIS   -9.4%    
EXEL        8.37% 
KRYS        1.93% 
TWST   -11.78%    
• View Complete Report
   



Partnership

Monte Rosa and Novartis Unite for Innovation Amidst Revenue Surge and Market Decline,

Published Mon, Sep 15 2025 11:18 AM UTC

Monte Rosa Therapeutics Collaborates with Novartis Amid Significant Revenue Growth and Market ChallengesMonte Rosa Therapeutics Inc. has recently announced a collaboration with Novartis to develop targeted degraders aimed at treating immune-mediated diseases. This partnership is expected to leverage both companies’ expertise in drug development to enhance treatment option...
Clinical Study

Innovating Oncology Monte Rosa Therapeutics Advances Molecular Glue Degraders in Breast Cancer and Beyond

Published Mon, Dec 30 2024 2:15 AM UTC

In the rapidly evolving landscape of oncology therapeutics, the innovations brought forth by Monte Rosa Therapeutics present a notable advancement in the targeted treatment of breast cancer and potentially other diseases. Recent presentations at prestigious medical conferences highlight promising preclinical data regarding the company’s CDK2-directed molecular glue degrade...
Clinical Study

Innovating Inflammation Monte Rosa Therapeutics MRT-6160 and MRT-8102 Pave the Way for Next-Generation IBD Treatment...

Published Mon, Aug 19 2024 11:00 AM UTC

Emerging Therapeutics: Advancements in the Development of MRT-6160 and MRT-8102 by Monte Rosa Therapeutics In the rapidly evolving landscape of targeted therapies for challenging health conditions, Monte Rosa Therapeutics is making significant strides with its innovative approaches to drug development. The recent announcements concerning the Phase 1 study of MRT-6160 and th...
Clinical Study

Unleashing Therapeutic Potential Monte Rosa Therapeutics Forging Ahead with MRT-2359, MRT-6160, and MRT-8102...

Published Thu, Jun 27 2024 11:00 AM UTC

Monte Rosa Therapeutics, a leading biotechnology company, has recently provided updates on the development progress of three promising therapeutic candidates: MRT-2359, MRT-6160, and MRT-8102. These advancements demonstrate the company s commitment to addressing unmet medical needs using innovative approaches such as molecular glues and pathway inhibitors. This article aims...
Clinical Study

Monte Rosa Therapeutics Unveils Promising Preclinical Data at Digestive Disease Week 2024, Propelling Excitement for a Revolutionary Treatment for Inflammatory Bowel Disease.

Published Tue, May 21 2024 11:00 AM UTC

Monte Rosa Therapeutics Presents Promising Preclinical Data at Digestive Disease Week 2024, Showcasing the Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseIn a significant development in the field of inflammatory bowel disease (IBD) research, Monte Rosa Therapeutics, a leading biotechnology company, has presented compelling preclinical data at Digestive Diseas...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 32.18
Price to Sales (Expected) -
Price to Book 2.65
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.97
Working Capital Ratio 6.07
Leverage Ratio (MRQ) 0.41
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.49 $
Revenues (TTM) 0.43 $
Cash Flow (TTM) 0.81 $
Cash 6.67 $
Book Value 5.23 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 286,353
Net Income per Employee (TTM) -866,760
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.09

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -1188.46 %
Net Margin (MRQ) -1057.08 %
Net Cash Flow Margin (MRQ) 711.85 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Monte Rosa Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.